Fund
Mubadala Capital
Page built from the operations logged, not from a written profile. It says nothing about the fund's activity outside the scope of Bolus, which is health venture capital in Europe and the United States.
- Operations logged
- 2
- Lead
- 0
- New entries
- 2
- Follow ons
- 0
- Latest operation
- 24 September 2026
- Sectors
- Medtech, Biotech
Operations
| Date | Company | Stage | Amount | Role |
|---|---|---|---|---|
| 24 Sept | United States, Medtech | Series D and later | 250 M$ | Participant |
| 13 Jan | United States, Biotech | Series B | 33,5 M$ | Participant |
Co investors 14 funds crossed
- Ackman Oxman Institute 1 operation
- ARK Invest 1 operation
- B Capital 1 operation
- Bison Ventures 1 operation
- Duquesne Family Office 1 operation
- Eli Lilly 1 operation
- Hitachi Ventures 1 operation
- Invus 1 operation
- Jefferson Life Sciences 1 operation
- JSL Health Capital 1 operation
- Korea Investment Partners 1 operation
- Manta Ray 1 operation
- Mirae Asset Capital 1 operation
- Pershing Square 1 operation
Funds that appeared in the same rounds, in any capacity. Geographies logged: United States.